Expression and clinical significance of 5‑HT and 5‑HT3R in the intestinal mucosa of patient with diarrhea‑type irritable bowel syndrome

Fu,Rui; Chen,Mingxian; Chen,Yu; Mao,Guoqun; Liu,Saiyue

doi:10.3892/etm.2019.7297

Expression and clinical significance of 5‑HT and 5‑HT3R in the intestinal mucosa of patient with diarrhea‑type irritable bowel syndrome

Authors:
- Rui Fu
- Mingxian Chen
- Yu Chen
- Guoqun Mao
- Saiyue Liu
View Affiliations

Affiliations: Department of Gastroenterology, Tongde Hospital of Zhejiang Province, hangzhou, Zhejiang 310012, P.R. China, Laboratory Animal Center, Zhejiang Province Academy of Traditional Chinese Medicine, hangzhou, Zhejiang 310012, P.R. China, Department of radiology, Tongde Hospital of Zhejiang Province, hangzhou, Zhejiang 310012, P.R. China, Department of Adverse Drug Reaction Monitoring, Zhejiang Province Center of Adverse Drug Reaction Monitoring, hangzhou, Zhejiang 310012, P.R. China
Published online on: February 22, 2019 https://doi.org/10.3892/etm.2019.7297
Pages: 3077-3082

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Expression levels and clinical significance of 5‑HT and 5‑HT3R in the intestinal mucosa tissue of patients with diarrhea‑type irritable bowel syndrome (D‑IBS) were investigated. A retrospective analysis was performed on 46 tissue specimens (observation group) of the intestinal mucosa of patients with D‑IBS, who were diagnosed in the Tongde Hospital of Zhejiang Province and received colonoscopy from March 2016 to December 2017, and 18 tissue specimens (control group) of the intestinal mucosa of healthy subjects who received physical examinations. The expression levels of 5‑HT and 5‑HT3R in the intestinal mucosa tissue of patients in the observation and control group were detected by ELISA, and the relationship between 5‑HT, 5‑HT3R and the clinicopathological parameters of patients with D‑IBS was analyzed. Pearson's correlation analysis was used to analyze the correlation of 5‑HT and 5‑HT3R in the intestinal mucosa tissue of patients with D‑IBS. The expression levels of 5‑HT and 5‑HT3R in the intestinal mucosa tissue of patients in the observation group were significantly higher than those of the patients in the control group (344.86±67.52 ng/ml and 13.04±8.34 pg/ml) (P<0.001). There was a positive correlation between the expression level of 5‑HT and the expression level of 5‑HT3R in the intestinal mucosa tissue of patients with D‑IBS (r=0.725, P<0.001). The expression levels of 5‑HT and 5‑HT3R in the intestinal mucosa tissue of patients with D‑IBS were both significantly higher than those of the healthy subjects. The expression levels of 5‑HT and 5‑HT3R in patients with D‑IBS were correlated with age, sex and the history of gastrointestinal infection. 5‑HT and 5‑HT3R may be involved in the pathogenesis of D‑IBS, and potentially used for clinical treatment.

View Figures

View References

1	Harper L and Bold J: An exploration into the motivation for gluten avoidance in the absence of coeliac disease. Gastroenterol Hepatol Bed Bench. 11:259–268. 2018.PubMed/NCBI
2	Fadgyas-Stanculete M, Buga AM, Popa-Wagner A and Dumitrascu DL: The relationship between irritable bowel syndrome and psychiatric disorders: From molecular changes to clinical manifestations. J Mol Psychiatry. 2:4–11. 2014. View Article : Google Scholar : PubMed/NCBI
3	Zhao YF, Ma XQ, Wang R, Yan XY, Li ZS, Zou DW and He J: Epidemiology of functional constipation and comparison with constipation-predominant irritable bowel syndrome: The Systematic Investigation of Gastrointestinal Diseases in China (SILC). Aliment Pharmacol Ther. 34:1020–1029. 2011. View Article : Google Scholar : PubMed/NCBI
4	Ma XP, Hong J, An CP, Zhang D, Huang Y, Wu HG, Zhang CH and Meeuwsen S: Acupuncture-moxibustion in treating irritable bowel syndrome: How does it work? World J Gastroenterol. 20:6044–6054. 2014. View Article : Google Scholar : PubMed/NCBI
5	Lee IS, Preissl H and Enck P: How to perform and interpret functional magnetic resonance imaging studies in functional gastrointestinal disorders. J Neurogastroenterol Motil. 23:197–207. 2017. View Article : Google Scholar : PubMed/NCBI
6	Rajendra S and Alahuddin S: Prevalence of irritable bowel syndrome in a multi-ethnic Asian population. Aliment Pharmacol Ther. 19:704–706. 2004. View Article : Google Scholar : PubMed/NCBI
7	Harris LA, Umar SB, Baffy N and Heitkemper MM: Irritable bowel syndrome and female patients. Gastroenterol Clin North Am. 45:179–204. 2016. View Article : Google Scholar : PubMed/NCBI
8	Labus JS, Dinov ID, Jiang Z, Ashe-McNalley C, Zamanyan A, Shi Y, Hong JY, Gupta A, Tillisch K, Ebrat B, et al: Irritable bowel syndrome in female patients is associated with alterations in structural brain networks. Pain. 155:137–149. 2014. View Article : Google Scholar : PubMed/NCBI
9	Saha L: Irritable bowel syndrome: Pathogenesis, diagnosis, treatment, and evidence-based medicine. World J Gastroenterol. 20:6759–6773. 2014. View Article : Google Scholar : PubMed/NCBI
10	Grundmann O and Yoon SL: Complementary and alternative medicines in irritable bowel syndrome: An integrative view. World J Gastroenterol. 20:346–362. 2014. View Article : Google Scholar : PubMed/NCBI
11	Rahman MM, Mahadeva S and Ghoshal UC: Epidemiological and clinical perspectives on irritable bowel syndrome in India, Bangladesh and Malaysia: A review. World J Gastroenterol. 23:6788–6801. 2017. View Article : Google Scholar : PubMed/NCBI
12	Crowell MD, Shetzline MA, Moses PL, Mawe GM and Talley NJ: Enterochromaffin cells and 5-HT signaling in the pathophysiology of disorders of gastrointestinal function. Curr Opin Investig Drugs. 5:55–60. 2004.PubMed/NCBI
13	Stasi C, Bellini M, Bassotti G, Blandizzi C and Milani S: Serotonin receptors and their role in the pathophysiology and therapy of irritable bowel syndrome. Tech Coloproctol. 18:613–621. 2014. View Article : Google Scholar : PubMed/NCBI
14	Glatzle J, Sternini C, Robin C, Zittel TT, Wong H, Reeve JR Jr and Raybould HE: Expression of 5-HT3 receptors in the rat gastrointestinal tract. Gastroenterology. 123:217–226. 2002. View Article : Google Scholar : PubMed/NCBI
15	Crowell MD: Role of serotonin in the pathophysiology of the irritable bowel syndrome. Br J Pharmacol. 141:1285–1293. 2004. View Article : Google Scholar : PubMed/NCBI
16	Wang LH, Fang XC and Pan GZ: Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesis. Gut. 53:1096–1101. 2004. View Article : Google Scholar : PubMed/NCBI
17	Mawe GM, Coates MD and Moses PL: Review article: Intestinal serotonin signalling in irritable bowel syndrome. Aliment Pharmacol Ther. 23:1067–1076. 2006. View Article : Google Scholar : PubMed/NCBI
18	Wang Y, Wu Z, Qiao H and Zhang Y: A genetic association study of single nucleotide polymorphisms in GNβ3 and COMT in elderly patients with irritable bowel syndrome. Med Sci Monit. 20:1246–1254. 2014. View Article : Google Scholar : PubMed/NCBI
19	Endo Y, Shoji T and Fukudo S: Epidemiology of irritable bowel syndrome. Ann Gastroenterol. 28:158–159. 2015.PubMed/NCBI
20	Luscombe FA: Health-related quality of life and associated psychosocial factors in irritable bowel syndrome: A review. Qual Life Res. 9:161–176. 2000. View Article : Google Scholar : PubMed/NCBI
21	Salaga M, Binienda A, Tichkule RB, Thakur GA, Makriyannis A, Storr M and Fichna J: The novel peripherally active cannabinoid type 1 and serotonin type 3 receptor agonist AM9405 inhibits gastrointestinal motility and reduces abdominal pain in mouse models mimicking irritable bowel syndrome. Eur J Pharmacol. 836:34–43. 2018. View Article : Google Scholar : PubMed/NCBI
22	Choung RS, Locke GR III, Zinsmeister AR, Schleck CD and Talley NJ: Psychosocial distress and somatic symptoms in community subjects with irritable bowel syndrome: A psychological component is the rule. Am J Gastroenterol. 104:1772–1779. 2009. View Article : Google Scholar : PubMed/NCBI
23	Chiba T, Yamamoto K, Sato S and Suzuki K: Long-term efficacy and safety of ramosetron in the treatment of diarrhea-predominant irritable bowel syndrome. Clin Exp Gastroenterol. 6:123–128. 2013. View Article : Google Scholar : PubMed/NCBI
24	Zhou Y, Zhou H and Liu B: Current status of study on 5-HT in the pathogenesis of irritable bowel syndrome. Chin J Gastroenterol. 16:445–448. 2011.(In Chinese).
25	Lee OY: Asian motility studies in irritable bowel syndrome. J Neurogastroenterol Motil. 16:120–130. 2010. View Article : Google Scholar : PubMed/NCBI
26	Kapeller J, Houghton LA, Mönnikes H, Walstab J, Möller D, Bönisch H, Burwinkel B, Autschbach F, Funke B, Lasitschka F, et al: First evidence for an association of a functional variant in the microRNA-510 target site of the serotonin receptor-type 3E gene with diarrhea predominant irritable bowel syndrome. Hum Mol Genet. 17:2967–2977. 2008. View Article : Google Scholar : PubMed/NCBI
27	Andresen V and Hollerbach S: Reassessing the benefits and risks of alosetron: What is its place in the treatment of irritable bowel syndrome? Drug Saf. 27:283–292. 2004. View Article : Google Scholar : PubMed/NCBI
28	Sun J, Wu X, Meng Y, Cheng J, Ning H, Peng Y, Pei L and Zhang W: Electro-acupuncture decreases 5-HT, CGRP and increases NPY in the brain-gut axis in two rat models of Diarrhea-predominant irritable bowel syndrome (D-IBS). BMC Complement Altern Med. 15:3402015. View Article : Google Scholar : PubMed/NCBI
29	Ford AC, Brandt LJ, Young C, Chey WD, Foxx-Orenstein AE and Moayyedi P: Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: Systematic review and meta-analysis. Am J Gastroenterol. 104:1831–1843. 2009. View Article : Google Scholar : PubMed/NCBI
30	Houghton LA, Foster JM and Whorwell PJ: Alosetron, a 5-HT3 receptor antagonist, delays colonic transit inpatients with irritable bowel syndrome and healthy volunteers. Aliment Pharmacol Ther. 14:775–782. 2000. View Article : Google Scholar : PubMed/NCBI
31	Talley NJ: Review article: 5-hydroxytryptamine agonists and antagonists in the modulation of gastrointestinal motility and sensation: clinical implications. Aliment Pharmacol Ther. 6:273–289. 1992. View Article : Google Scholar : PubMed/NCBI
32	Spiller RC: Targeting the 5-HT(3) receptor in the treatment of irritable bowel syndrome. Curr Opin Pharmacol. 11:68–74. 2011. View Article : Google Scholar : PubMed/NCBI
33	Thompson WG, Irvine EJ, Pare P, Ferrazzi S and Rance L: Functional gastrointestinal disorders in Canada: First population-based survey using Rome II criteria with suggestions for improving the questionnaire. Dig Dis Sci. 47:225–235. 2002. View Article : Google Scholar : PubMed/NCBI
34	Qin HY, Cheng CW, Tang XD and Bian ZX: Impact of psychological stress on irritable bowel syndrome. World J Gastroenterol. 20:14126–14131. 2014. View Article : Google Scholar : PubMed/NCBI
35	Jarcho JM, Chang L, Berman M, Suyenobu B, Naliboff BD, Lieberman MD, Ameen VZ, Mandelkern MA and Mayer EA: Neural and psychological predictors of treatment response in irritable bowel syndrome patients with a 5-HT3 receptor antagonist: A pilot study. Aliment Pharmacol Ther. 28:344–352. 2008. View Article : Google Scholar : PubMed/NCBI
36	Han SH, Lee OY, Bae SC, Lee SH, Chang YK, Yang SY, Yoon BC, Choi HS, Hahm JS, Lee MH, et al: Prevalence of irritable bowel syndrome in Korea: Population-based survey using the Rome II criteria. J Gastroenterol Hepatol. 21:1687–1692. 2006. View Article : Google Scholar : PubMed/NCBI
37	Mulak A, Taché Y and Larauche M: Sex hormones in the modulation of irritable bowel syndrome. World J Gastroenterol. 20:2433–2448. 2014. View Article : Google Scholar : PubMed/NCBI